ArticleDiabetes, obesity & metabolism2026

Cardiorenal Outcomes of Empagliflozin Versus Dapagliflozin in Secondary Prevention Among Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Nationwide Cohort Study.

Sangwoo Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.